GlaxoSmithKline - Database of Clinical Trials by Pharmaceutical Companies

All Categories Pharma Companies » GlaxoSmithKline

Influenza Burden Assessment in the United States, July 1997 - up to April 2009

Condition: Influenza
Intervention: Other: Data collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Sage Analytica
Not yet recruiting - verified May 2012
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Condition: Melanoma
Interventions: Drug: Dabrafenib; Drug: Vemurafenib; Drug: Trametinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012
BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia.

Condition: Systemic Lupus Erythematosus
Intervention: Drug: Belimumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Human Genome Sciences
Not yet recruiting - verified May 2012
A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™

Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: Maraviroc; Drug: Combivir; Drug: GSK2838510
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified May 2012
The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hypersensitivity.

Condition: Dentine Hypersensitivity
Interventions: Drug: Stannous Fluoride; Drug: Sodium Monofluorophosphate
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified May 2012
Impact on Quality of Hospital Care During Pre- and Post- Rotavirus (RV) Vaccination Introduction in Belgium

Condition: Gastroenteritis
Intervention: Other: Data collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012
Pertussis Infection in Adolescents and Adults With Prolonged Cough

Condition: Bordetella Pertussis Infection
Interventions: Procedure: Blood collection; Other: Data collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012
Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity

Condition: Dentine Hypersensitivity
Interventions: Drug: Stannous Fluoride; Drug: Sodium Monofluorophosphate
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified May 2012
Study on the Burden of Influenza-related Hospitalizations and Emergency Room (ER) Visits in Children in Spain

Condition: Influenza
Interventions: Procedure: Throat swab and/or nasopharyngeal swab; Other: Data collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified May 2012
Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)

Condition: Ovarian Cancer
Intervention: Drug: pazopanib in combination with weekly topotecan
Sponsors: Charite University, Berlin, Germany; JSehouli; GlaxoSmithKline
Not yet recruiting - verified May 2012
A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

Condition: Lupus Erythematosus, Systemic
Interventions: Biological: Belimumab plus Early Vaccination; Biological: Belimumab plus Late Vaccination
Sponsors: Human Genome Sciences; Human Genome Sciences; GlaxoSmithKline
Not yet recruiting - verified May 2012
Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy

Condition: Epilepsy
Interventions: Drug: retigabine/ezogabine; Drug: lacosamide; Drug: zonisamide; Drug: pregabalin; Drug: eslicarbazepine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

Condition: Sarcoma
Interventions: Drug: Gemcitabine and Pazopanib; Drug: Gemcitabine and Docetaxel
Sponsors: Medical University of South Carolina; Medical University of South Carolina; GlaxoSmithKline
Not yet recruiting - verified May 2012
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects

Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 Oral; Drug: GSK1265744 LAP 800mg intramuscular injection; Drug: GSK1265744 LAP 200mg subcutaneous injection; Drug: GSK1265744 LAP 200mg intramuscular injection; Drug: GSK1265744 LAP 400mg intramuscular injection; Drug: TMC278 LA 1200mg intramuscular injection; Drug: TMC278 LA 600mg intramuscular injection; Drug: GSK1265744 LAP 800mg intramuscular injection
Sponsors: ViiV Healthcare; ViiV Healthcare; GlaxoSmithKline
Not yet recruiting - verified May 2012
Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme

Condition: Newly Diagnosed Glioblastoma Multiforme
Intervention: Other: Lapatinib/Temozolomide/radiation
Sponsors: Jonsson Comprehensive Cancer Center; Jonsson Comprehensive Cancer Center; GlaxoSmithKline
Recruiting - verified May 2012
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease

Condition: Anaemia
Interventions: Drug: GSK1278863; Drug: rhEPO
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Pharmaceutical Product Development Clinical Research Organization (CRO)
Not yet recruiting - verified May 2012
WEUKBRE5559: IMI PROTECT: Benzodiazepines & Fracture

Condition: Anxiety Disorders
Intervention: Drug: Benzodiazepine (BZD) use, defined by ATC codes
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
IMI PROTECT(WP2): Antidepressants & Fractures

Condition: Anxiety Disorder
Intervention: Drug: Tricyclic AD (TCAs) and selective serotonin re-uptake inhibitors (SSRIs) antidepressants
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
IMI PROTECT (Work Package 2): Calcium Channel Blockers and Cancer

Condition: Hypertension
Intervention: Drug: CCB use
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics

Condition: Infections, Bacterial
Intervention: Drug: Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus

Condition: Strabismus
Intervention: Drug: GSK1358820
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Condition: Melanoma
Interventions: Drug: dabrafenib plus trametinib; Drug: dabrafenib plus trametinib placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345.

Condition: Cough
Interventions: Drug: GSK2339345 (Inhaled) Single Dose; Other: Placebo (Inhaled) Single Dose; Drug: GSK2339345 (Inhaled) Repeat Dose; Other: Placebo (Inhaled) Repeat Dose
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis

Condition: Anaemia
Interventions: Drug: GSK1278863; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Pharmaceutical Product Development Clinical Research Organization (CRO)
Not yet recruiting - verified April 2012
A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects

Condition: Insufficient Information
Interventions: Drug: sibutramine; Other: sibutramine placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified May 2012
Rechallenge, Potential Drug Induced Liver Injury (Kaiser)

Condition: Drug-induced Liver Injury
Intervention: Drug: Prescription drugs with known hepatotoxicity
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
Study of Belimumab Administered Subcutaneously to Healthy Subjects

Condition: Healthy
Interventions: Biological: Single Dose Group: Belimumab IV 240 mg; Biological: Single Dose Group: Belimumab SC 2 x 120 mg; Biological: Single Dose Group: Belimumab SC 1 x 240 mg; Biological: Single Dose Group: Belimumab SC 1 x 200 mg; Biological: Multiple Dose Group: Belimumab SC 2 x 120 mg weekly; Biological: Multiple Dose Group: Belimumab SC 1 x 200 mg weekly
Sponsors: Human Genome Sciences; Human Genome Sciences; GlaxoSmithKline
Completed - verified April 2012
Duration of Postoperative Antibiotic Prophylaxis in Facial Fractures

Condition: Surgical Wound Infection
Interventions: Drug: Amoxicillin/clavulanic acid; Drug: Amoxicillin plus placebo
Sponsors: University Hospital Inselspital, Berne; University Hospital Inselspital, Berne; Schweizerische Unfallversicherung SUVA, Switzerland; Mepha Parma AG, Switzerland; GlaxoSmithKline AG, Switzerland
Recruiting - verified April 2012
Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers

Conditions: Haemophilus Influenzae Type b Diseases; Diphtheria; Poliomyelitis; Pertussis; Tetanus
Intervention: Biological: Infanrix-IPV+HibTM
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified April 2012
Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fed Condition

Condition: Fed
Interventions: Drug: Ondansetron Tablets USP 8 mg; Drug: Ondansetron Hydrochloride
Sponsors: IPCA Laboratories Ltd.; IPCA Laboratories Ltd.
Completed - verified April 2012
Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fasting Condition

Condition: Fasting State
Interventions: Drug: Ondansetron Tablets USP 8 mg; Drug: Ondansetron Hydrochloride
Sponsors: IPCA Laboratories Ltd.; IPCA Laboratories Ltd.
Completed - verified April 2012
Bioequivalence Study of Carvedilol Tablets USP 12.5 mg Under Fasting Condition

Condition: Fasting State
Interventions: Drug: Carvedilol Tablets USP 12.5 mg; Drug: Carvedilol
Sponsors: IPCA Laboratories Ltd.; IPCA Laboratories Ltd.
Completed - verified April 2012
A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors

Condition: Cancer
Intervention: Drug: GSK2118436
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified April 2012
Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma

Condition: Asthma
Interventions: Drug: FF/GSK573719; Drug: FF/GSK573719; Drug: FF/GSK573719; Drug: FF/GSK573719; Drug: FF/GSK573719; Drug: FF; Drug: FF/VI
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Herpes Simplex Type 1 Suppression in Hepatitis C

Condition: Chronic Hepatitis C Infection
Interventions: Drug: Valacyclovir; Drug: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; GlaxoSmithKline
Recruiting - verified April 2012
Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Inhaled GSK573719; Drug: Inhaled GSK573719/vilanterol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC)

Condition: Carcinoma, Midline
Intervention: Drug: GSK525762
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea

Conditions: Poliomyelitis; Pertussis; Diphtheria; Tetanus
Intervention: Other: Infanrix-IPV data collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012
Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety

Condition: Dermatitis, Eczematous
Interventions: Drug: Clobetasone Butyrate 0.05% Cream; Drug: Vehicle (base cream)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
To Evaluate the Safety, Tolerability and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam in Pediatric Subjects (Ages 2-11) With Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: STF 115469 Foam; Drug: Vehicle Foam
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012
A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Inhaled GSK573719/vilanterol; Drug: Inhaled GSK573719
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057

Condition: Respiratory Disorders
Interventions: Drug: GSK1995057; Procedure: bronchoalveolar lavage; Drug: LPS; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Ezetimibe Bioequivalance Study

Condition: Hypercholesterolaemia
Interventions: Drug: 10mg Ezetimibe; Drug: 10 mg Ezetimibe - wash out period
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified May 2012
Guaifenesin - Muscle Relaxant - Upper Back Pain

Condition: Upper Back Pain
Interventions: Drug: Guaifenesin; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified March 2012
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir

Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: dolutegravir 50 mg twice daily; Drug: dolutegravir placebo twice daily; Drug: Open-label dolutegravir 50mg twice daily
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Recruiting - verified May 2012
A Dose-ranging Study of Fluticasone Furoate (FF)

Condition: Asthma
Interventions: Drug: Fluticasone Furoate; Drug: Fluticasone Propionate; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified March 2012
A Single Dose Pharmacokinetics (PK) Study of GSK2434735 in Healthy Male Volunteers

Condition: Asthma
Interventions: Drug: Intravenous (IV) single dose; Drug: Subcutaneous (SC) single dose
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed

Condition: Epilepsy
Interventions: Drug: Digoxin Alone; Drug: Digoxin + Retigabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Drug: chlorambucil, tablets; Drug: ofatumumab (GSK1841157) infusion
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified March 2012
A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: GSK189075A; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics

Condition: Rhinitis
Interventions: Drug: Levoceitirizine; Drug: Levocetirizine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: DTG; Drug: BCV; Drug: TVR
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Active, not recruiting - verified April 2012
To Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Calcipotriene 0.005%, Applied Under Maximal Use Conditions in 12-16 Year Olds With Plaque Psoriasis

Condition: Psoriasis
Intervention: Drug: calcipotriene
Sponsors: GlaxoSmithKline; Stiefel, a GSK Company; GlaxoSmithKline
Recruiting - verified April 2012
Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka

Condition: Human Papillomavirus Infection
Interventions: Other: Cervarix data collection; Other: Data Collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified April 2012
A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)

Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children

Condition: Asthma
Interventions: Drug: Fluticasone propionate 100mcg; Drug: Placebo; Drug: Vilanterol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified April 2012
Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

Condition: Malaria, Falciparum
Intervention: Biological: RTS,S, FMP1
Sponsors: Walter Reed Army Institute of Research (WRAIR); US Army Surgeon General; GlaxoSmithKline
Completed - verified March 2012
Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children

Condition: Pneumococcal Disease
Interventions: Biological: Pneumococcal vaccine GSK2189242A; Biological: Placebo; Biological: Prevnar 13®; Biological: PedvaxHIB®
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified April 2012
Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2006-2007

Condition: Gastroenteritis
Intervention: Other: Data collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified March 2012
Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2010-2011

Condition: Gastroenteritis
Intervention: Other: Data collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified March 2012
A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: FF/VI; Other: Existing Maintenance Therapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Condition: High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Interventions: Drug: Ofatumumab; Drug: Etoposide; Drug: Cytarabine
Sponsors: University of California, San Francisco; C. Babis Andreadis; University of California, San Francisco; GlaxoSmithKline
Not yet recruiting - verified March 2012
Second-line Pazopanib Renal Cell Carcinoma (RCC) Study

Condition: Renal Cell Carcinoma
Intervention: Drug: Pazopanib
Sponsors: All Ireland Cooperative Oncology Research Group; All Ireland Cooperative Oncology Research Group; GlaxoSmithKline
Recruiting - verified March 2012
A Pharmacokinetic Study to Compare Sustained Release and Standard Paracetamol Formulations.

Condition: Healthy Volunteers
Interventions: Drug: Reference Therapy; Drug: Sustained Release Paracetamol; Drug: Sustained Release Paracetamol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol

Condition: Asthma
Interventions: Drug: SERETIDE Rotacaps; Drug: SERETIDE Diskus
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol® Extend

Condition: Healthy Volunteers
Interventions: Drug: Marketed paracetamol; Drug: Experimental paracetamol formulation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®

Condition: Healthy Volunteer
Interventions: Drug: Marketed paracetamol; Drug: Experimental paracetamol formulation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
Early Detection of COPD Patients in GOLD 0 (Smokers) Population

Conditions: COPD; Smoking; Other Diagnoses, Comorbidities, and Complications
Intervention:
Sponsors: Children's Hospital Srebrnjak; Children's Hospital Srebrnjak; GlaxoSmithKline; University Hospital Rijeka; Clinical Hospital Center, Split; General Hospital Dubrovnik; Institute for Medical Research and Occupational Health, Zagreb
Recruiting - verified March 2012
A Study of Belimumab in the Prevention of Kidney Transplant Rejection

Condition: Transplantation, Organ
Interventions: Drug: Belimumab (10mg/kg) will be given as an intravenous solution over a 1 hour time period week 0, week 2, week 4, week 8, week 12, week 16 and week 20.; Drug: Placebo (to match belimumab) will be given as an intravenous solution over a 1 hour time period at week 0, week 2, week 4, week 8, week 12, week 16 and week 20.
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified March 2012
Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformin in Healthy Indian Volunteers

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Metformin hydrochloride prolonged release; Drug: metformin hydrochloride prolonged release; Drug: Metformin hydrochloride sustained release/Glimepiride
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
Effect of Dentifrice Usage Regime on Efficacy of Fluoride in Situ

Condition: Dental Caries
Interventions: Drug: Fluoride Toothpaste; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: GSK1605786A; Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278

Condition: Huntingtons Disease
Interventions: Drug: GSK356278; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
Continuation Study of the Oral AKT Inhibitor GSK2110183

Condition: Cancer
Intervention: Drug: GSK2110183
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Losmapimod; Drug: Placebo
Sponsors: Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Technology Strategy Board; GlaxoSmithKline; Royal Brompton & Harefield NHS Foundation Trust; University of Cambridge
Not yet recruiting - verified February 2012
GW824575 First Time in Human

Condition: Retinal Diseases
Interventions: Drug: GW824575; Drug: GW824575 matched-placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012
Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Condition: Metastatic Solid Tumors
Intervention: Drug: PZP115891, PCI-24781
Sponsors: University of California, San Francisco; Pamela Munster; GlaxoSmithKline; Pharmacyclics
Not yet recruiting - verified February 2012
Dolutegravir Expanded Access Study

Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: dolutegravir
Sponsors: ViiV Healthcare; ViiV Healthcare; GlaxoSmithKline
Available - verified December 2011
Benlysta Pregnancy Registry

Conditions: Systemic Lupus Erythematosus; Pregnancy
Intervention: Drug: belimumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volunteers

Condition: Hypothyroidism
Interventions: Drug: Levothyroxine; Drug: Levothyroxine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

Condition: Multiple Sclerosis
Interventions: Drug: Ofatumumab 100; Drug: Ofatumumab 300; Drug: Ofatumumab 700; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012
Bupropion & Cardio Birth Defect (Slone)

Condition: Depression
Interventions: Drug: Exposure to any bupropion during the first trimester; Drug: Exposure to bupropion alone during the first trimester; Other: Referent group: no exposure to any anti-depressant or anti-smoking drug during pregnancy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified May 2012
Effects of Salmeterol on Autonomic Nervous System

Condition: Pulmonary Disease, Chronic Obstructive
Intervention: Drug: Salmeterol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified April 2012
Cardiovascular Events in Parkinson's Disease Patients

Conditions: Cardiovascular Event; Parkinson Disease
Intervention: Drug: levodopa
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012
Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma

Condition: Sarcoma, Soft-tissue
Intervention: Drug: pazopanib
Sponsors: University of Heidelberg; University of Heidelberg; University Hospital Mannheim; Klinikum Frankfurt Höchst; German Cancer Research Center; GlaxoSmithKline
Not yet recruiting - verified February 2012
Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436

Condition: Papillary Thyroid Carcinoma
Intervention: Drug: GSK2118436
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; GlaxoSmithKline
Not yet recruiting - verified April 2012
An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)

Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: Ofatumumab with GSK2110183
Sponsors: University Health Network, Toronto; University Health Network, Toronto; GlaxoSmithKline
Recruiting - verified February 2012
Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fasting Conditions

Condition: Healthy
Intervention: Drug: Ondansetron
Sponsors: Ranbaxy Inc.; Ranbaxy Laboratories Limited
Completed - verified February 2012
Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fed Conditions

Condition: Healthy
Intervention: Drug: Ondansetron
Sponsors: Ranbaxy Inc.; Ranbaxy Laboratories Limited
Completed - verified February 2012
A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies

Condition: Advanced Solid Tumors
Interventions: Drug: Carboplatin; Drug: Pazopanib
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance; GlaxoSmithKline
Not yet recruiting - verified February 2012
Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma

Conditions: Adult Alveolar Soft-part Sarcoma; Adult Angiosarcoma; Adult Desmoplastic Small Round Cell Tumor; Adult Epithelioid Hemangioendothelioma; Adult Epithelioid Sarcoma; Adult Extraskeletal Chondrosarcoma; Adult Extraskeletal Osteosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Malignant Fibrous Histiocytoma; Adult Malignant Hemangiopericytoma; Adult Malignant Mesenchymoma; Adult Neurofibrosarcoma; Adult Rhabdomyosarcoma; Adult Synovial Sarcoma; Childhood Alveolar Soft-part Sarcoma; Childhood Angiosarcoma; Childhood Desmoplastic Small Round Cell Tumor; Childhood Epithelioid Hemangioendothelioma; Childhood Epithelioid Sarcoma; Childhood Fibrosarcoma; Childhood Leiomyosarcoma; Childhood Liposarcoma; Childhood Malignant Hemangiopericytoma; Childhood Malignant Mesenchymoma; Childhood Neurofibrosarcoma; Childhood Synovial Sarcoma; Dermatofibrosarcoma Protuberans; Metastatic Childhood Soft Tissue Sarcoma; Nonmetastatic Childhood Soft Tissue Sarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: gemcitabine hydrochloride; Drug: pazopanib hydrochloride; Other: placebo; Other: laboratory biomarker analysis
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI); GlaxoSmithKline
Recruiting - verified March 2012
Study to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in Spain

Conditions: Herpes Zoster; Postherpetic Neuralgia
Intervention: Other: Data collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified March 2012
Study Assessing Lung Function in Healthy Volunteers Following Single Inhalations of an Inhaled Bronchodilator From Two Configurations a Dry Powder Inhaler.

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: GSK573719 62.5 mcg (one strip); Drug: GSK573719 62.5 mcg(two strips); Drug: GSK573719 125 mcg (one strip); Drug: GSK573719 125 mcg(two strips); Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012
A Study to Evaluate the Pharmacokinetics of Benzoic Acid and Hippuric Acid After Topical Administration of GSK2585823 in Japanese Subjects With Acne Vulgaris

Condition: Acne Vulgaris
Intervention: Drug: GSK2585823
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012
The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury

Condition: Lung Injury, Acute
Interventions: Drug: Dose 1 GSK2586881; Drug: Dose 2 GSK2586881; Drug: Dose 3 GSK2586881; Drug: Dose 4 GSK2586881; Drug: Placebo (saline)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012
QTc Study GSK573719+GW642444

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Placebo Moxifloxacin; Drug: Moxifloxacin; Drug: GSK573719/Vilanterol 125/25mcg; Drug: GSK573719; Drug: GSK573719/Vilanterol 500/100mcg; Drug: Placebo DPI
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma

Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012
Cost of Illness Associated With Influenza in the UK

Condition: Influenza
Intervention: Other: Data collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified January 2012
Influenza Burden Assessment in the United Kingdom, 1996-2008

Condition: Influenza
Intervention: Other: Data collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Sage Analytica
Active, not recruiting - verified January 2012
For Cause Prostate Biopsy in REDUCE Population Trial

Condition: Early Detection of Cancer
Intervention:
Sponsors: The Cleveland Clinic; The Cleveland Clinic; GlaxoSmithKline
Completed - verified January 2012
3 Grams Daily Valacyclovir in Chronic Hepatitis C Infection (Phase II)

Condition: Chronic Hepatitis C Infection
Interventions: Drug: Valacyclovir; Drug: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; GlaxoSmithKline
Recruiting - verified January 2012
Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528

Condition: Parkinson Disease
Intervention: Drug: Requip PR
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified May 2012
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Biological: Ofatumumab; Drug: Bendamustine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers

Condition: Restless Legs Syndrome
Interventions: Drug: GEn 1200mg; Drug: Gen 6000 mg; Drug: GEn Placebo; Drug: Moxifloxacin Placebo; Drug: Moxifloxacin
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable COPD

Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Procedure: Blood collection; Procedure: Swab collection; Procedure: Sputum collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations

Conditions: Asthma; Viral Infection
Interventions: Drug: Mepolizumab; Drug: Placebo
Sponsors: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); The Netherlands Asthma Foundation; GlaxoSmithKline
Recruiting - verified February 2012
Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib

Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Pazopanib
Sponsors: Scandinavian Sarcoma Group; Scandinavian Sarcoma Group; GlaxoSmithKline
Recruiting - verified January 2012
Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fed Condition

Condition: Healthy
Interventions: Drug: Lamotrigine; Drug: Lamictal®
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified October 2002
Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fasting Condition

Condition: Healthy
Interventions: Drug: Lamotrigine; Drug: Lamictal®
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified October 2002
Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary Care

Condition: Pulmonary Disease, Chronic Obstructive
Intervention: Procedure: Spirometry
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children

Conditions: Varicella; Rubella; Measles; Mumps
Interventions: Biological: Priorix Tetra; Biological: Meningitec
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults

Condition: Influenza
Intervention:
Sponsors: Dalhousie University; Dalhousie University; Public Health Agency of Canada (PHAC); Canadian Institutes of Health Research (CIHR); GlaxoSmithKline
Recruiting - verified January 2012
Bioequivalence Study for Ondansetron Hydrochloride Tablets 8 mg Under Fasting Condition

Condition: Healthy
Interventions: Drug: Ondansetron Hydrochloride; Drug: Ondansetron Hydrochloride
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified October 2006
Bioequivalence Study for Ondansetron Hydrochloride Tablets 8 mg Under Fed Condition

Condition: Healthy
Interventions: Drug: Ondansetron Hydrochloride; Drug: Ondansetron Hydrochloride
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified October 2006
Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma

Condition: Lymphoma
Interventions: Drug: Lamivudine; Drug: Tenofovir disoproxil fumarate
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; GlaxoSmithKline; Gilead Sciences
Not yet recruiting - verified February 2012
Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma

Condition: Advanced Renal Cell Carcinoma
Intervention: Drug: Pazopanib + interferon alpha 2A
Sponsors: Spanish Oncology Genito-Urinary Group; Spanish Oncology Genito-Urinary Group; GlaxoSmithKline
Recruiting - verified April 2010
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Conditions: Liposarcoma; Surgically Unresectable Liposarcoma; Metastatic Liposarcoma
Intervention: Drug: Pazopanib
Sponsors: ACORN Research, LLC; ACORN Research, LLC; GlaxoSmithKline
Recruiting - verified April 2012
A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)

Condition: Postoperative Nausea and Vomiting
Interventions: Drug: Ondansetron; Drug: Vestipitant
Sponsors: Octagon Research Solutions, Inc.; Octagon Research Solutions, Inc.
Recruiting - verified May 2012
An Investigation of the Safety and Utility of Treximet in the Treatment of Menstrual Migraine

Condition: Menstrual Migraine
Intervention: Other: Diary
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; GlaxoSmithKline
Recruiting - verified April 2012
A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema

Condition: Diabetic Macular Edema
Interventions: Drug: darapladib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified February 2012
Cervarix Long-term Safety Surveillance

Conditions: Myositis; Guillain-Barre Syndrome; Autoimmune Thyroiditis; Multiple Sclerosis; Cutaneous Lupus; Lupus Erythematosus; Inflammatory Arthritis; Type 1 Diabetes; Central Demyelination; Dermatomyositis; Idiopathic Thrombocytopenic Purpura; Graves Disease
Interventions: Biological: Cervarix; Other: Data collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified January 2012
Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.

Condition: Asthma
Interventions: Drug: GW685698/GW642444; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

Condition: Purpura, Thrombocytopenic, Idiopathic
Interventions: Drug: Eltrombopag; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Japanese phase1 Study of Belimumab (IV vs SC)

Condition: Systemic Lupus Erythematosus
Interventions: Drug: GSK1550188 IV; Drug: GSK1550188 SC
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry

Condition: Asthma
Interventions: Drug: GW685698/GW642444; Drug: CCI18781
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
A Multiple Use Tolerability Study of a Breathe Right Nasal Strip Prototype

Condition: Healthy Volunteers
Interventions: Device: Marketed Nasal Strip; Device: Prototype Nasal Dilator
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified December 2011
A Study Assessing a Range of Formulations of the Fixed Dose Combination Product Containing Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) to Find a Formulation Which is Bioequivalent to Harnal-D Tablets (Tamsulosin Hydrochloride, 0.2mg) in Healthy Male Subjects From North East Asia

Condition: Prostatic Hyperplasia
Interventions: Drug: Dutasteride (0.5mg, fasted state); Drug: Dutasteride (0.5mg, fed state); Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state); Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state); Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state); Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state); Drug: Harnal-D Tablets with water (fasted state); Drug: Harnal-D Tablets with water (fed state); Drug: Harnal-D tablets without water (fasted state)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified December 2011
A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: 1mg Glimepiride/10mg Atorvastatin FDC; Drug: 2mg Glimepiride/10mg Atorvastatin FDC; Drug: 3mg Glimepiride/10mg Atorvastatin FDC; Drug: 4mg Glimepiride/10mg Atorvastatin FDC; Drug: 1mg Glimepiride/20mg Atorvastatin FDC; Drug: 2mg Glimepiride/20mg Atorvastatin FDC; Drug: 3mg Glimepiride/20mg Atorvastatin FDC; Drug: 4mg Glimepiride/20mg Atorvastatin FDC; Drug: 1mg Glimepiride; Drug: 2mg Glimepiride; Drug: 3mg Glimepiride; Drug: 4mg Glimepiride; Drug: 10mg Atorvastatin; Drug: 20mg Atorvastatin
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab

Condition: Osteoporosis, Postmenopausal
Interventions: Drug: denosumab; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012
Provoked Craving Assessment

Conditions: Smoking Dependence; Smoking
Interventions: Drug: oral nicotine; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
Cherry Nicotine Lozenge BE Study

Condition: Smoking
Interventions: Drug: nicotine polacrilex; Drug: nicotine polacrilex
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers

Condition: Community-acquired Infection
Interventions: Drug: GSK2251052 750 mg; Drug: GSK2251052 1500 mg; Drug: GSK2251052 1500 mg BID; Drug: GSK2251052 2250 mg; Drug: GSK2251052 3000 mg; Drug: GSK2251052 0.9% saline
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Suspended - verified February 2012
A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)

Conditions: Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma
Intervention: Drug: Eltrombopag and Vorinostat
Sponsors: Peter MacCallum Cancer Centre, Australia; Peter MacCallum Cancer Centre, Australia; GlaxoSmithKline; Merck
Not yet recruiting - verified December 2011
Adefovir and Lamivudine for Entecavir Resistance (ALTER Study)

Condition: Chronic Hepatitis B
Intervention: Drug: ADEFOVIR, LAMIVUDINE
Sponsors: Korea University; Korea University; GlaxoSmithKline
Active, not recruiting - verified March 2012
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma

Conditions: Locally Advanced and/or Metastatic Renal Cell Carcinoma; Carcinoma, Renal Cell; Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Pazopanib
Sponsors: iOMEDICO AG; iOMEDICO AG; GlaxoSmithKline
Recruiting - verified February 2012
Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol

Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Ortho-Cyclen; Drug: Dolutegravir; Drug: Placebo
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Completed - verified April 2012
Lapatinib and Bortezomib in Patients With Advanced Malignancies

Condition: Advanced Solid Tumors
Intervention: Drug: Lapatinib and bortezomib
Sponsors: Georgetown University; Georgetown University; GlaxoSmithKline; Millennium Pharmaceuticals, Inc.
Recruiting - verified December 2011
Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL)

Conditions: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
Interventions: Drug: High Dose Methylprednisolone; Drug: Ofatumumab; Drug: Lenalidomide; Drug: Sargramostim
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; GlaxoSmithKline; Celgene Corporation
Recruiting - verified January 2012
A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection

Condition: Influenza, Human
Intervention: Drug: 600mg intravenous (IV) zanamivir
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.

Condition: Asthma
Interventions: Drug: GW685698X (fluticasone furoate) 100mcg Morning; Drug: GW685698X (fluticasone furoate) 100mcg Evening; Drug: GW685698X (fluticasone furoate) 250mcg Evening; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified December 2011
Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: High Dose Methylprednisolone; Drug: Ofatumumab; Drug: Lenalidomide; Drug: Sargramostim
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; GlaxoSmithKline; Celgene Corporation
Recruiting - verified January 2012
A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects

Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: Dolutegravir
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Recruiting - verified March 2012
Study of How Well Letrozole Works in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer

Conditions: Breast Neoplasms; Endocrine Breast Diseases; Neoplasm Metastasis
Interventions: Drug: letrozole; Drug: lapatinib; Drug: everolimus
Sponsors: University of Maryland; University of Maryland; Novartis Pharmaceuticals; GlaxoSmithKline
Not yet recruiting - verified December 2011
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers

Conditions: Haemophilus Influenzae Infections; Streptococcus Pneumoniae Disease
Interventions: Biological: Pneumococcal vaccine GSK2830930A; Biological: Synflorix™
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
Serological Response to Porcine Circovirus Type 1 (PCV-1) and PCV-1 DNA in Stools of Infants Following Administration of Rotarix™

Conditions: Rotavirus Infection; Evidence of PCV-1 Replication and/or Immune Response to the PCV-1 in HRV Vaccinated Infants
Interventions: Procedure: Stool sample; Procedure: Serum sample
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012
Effect of a New Long-acting beta2-agonist (LABA)/Long-acting Muscarinic Antagonist (LAMA) Combination Versus LAMA Alone on Exercise in GOLD Stage II Chronic Obstructive Pulmonary Disease

Condition: COPD
Interventions: Drug: GSK573719/GW642444; Drug: GSK573719
Sponsors: Queen's University; Queen's University; GlaxoSmithKline
Not yet recruiting - verified December 2011
Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia

Conditions: Sarcoma, Soft Tissue; Osteosarcoma; Neoplasms, Connective and Soft Tissue
Intervention: Drug: Eltrombopag
Sponsors: Duke University; Duke University; GlaxoSmithKline
Enrolling by invitation - verified April 2012
A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease

Condition: Parkinson Disease
Interventions: Drug: ropinirole monotherapy; Drug: placebo monotherapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012
Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol Combination

Condition: Asthma
Interventions: Drug: Fluticasone Furoate (200mcg unit strength); Drug: Fluticasone Furoate/Vilanterol (200/25mcg unit strength)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects

Condition: Crohn's Disease
Intervention: Drug: GSK1605786
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified December 2011
Study in Pediatric Subjects With Epilepsy

Condition: Epilepsy
Intervention: Drug: ezogabine/retigabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Valeant Pharmaceuticals International, Inc.
Not yet recruiting - verified April 2012
A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease

Condition: Parkinson Disease
Interventions: Drug: ropinirole/L-dopa; Drug: placebo/L-dopa
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified February 2012
BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients

Condition: Bladder Cancer
Interventions: Biological: MAGE-A3 ASCI; Biological: BCG
Sponsors: University of Lausanne Hospitals; Patrice Jichlinski; Ludwig Center for Cancer Research of the University of Lausanne; GlaxoSmithKline
Enrolling by invitation - verified February 2012
Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue

Condition: Chronic Hepatitis B
Interventions: Drug: GSK548470 300 mg tablet; Drug: ETV 0.5 mg capsule
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy

Condition: Muscular Dystrophies
Intervention: Drug: GSK2402968
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics.

Condition: Rhinitis, Allergic, Seasonal
Interventions: Drug: 2 ng GSK2445053; Drug: 20ng GSK2445053; Drug: 100ng GSK2445053; Drug: 200ng GSK2445053; Drug: 400ng GSK2445053; Drug: 1000ng GSK2445053; Drug: 2000ng GSK2445053; Drug: 4000ng GSK2445053; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011
Severe Pandemic H1N1 Infection in ICU: Comparative Resource Utilization

Condition: Novel H1N1 Influenzal Acute Respiratory Infection
Intervention: Other: We will compare the resources used by both groups
Sponsors: University of Manitoba; University of Manitoba; GlaxoSmithKline
Completed - verified December 2011
Study on the Incidence of Intussusception (IS) in Children Aged < 12 Months in Japan

Condition: Intussusception
Intervention: Other: Data collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified November 2011
Dose Escalation Study of Pazopanib Plus TH-302

Condition: Solid Tumors
Intervention: Drug: Pazopanib and TH-302
Sponsors: Duke University; Duke University; National Comprehensive Cancer Network; GlaxoSmithKline; Threshold Pharmaceuticals
Recruiting - verified January 2012
Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic Treatment

Condition: Pneumonia Ventilator Associated
Interventions: Drug: Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin; Drug: compare 8 to15 days of antibiotic treatment
Sponsors: Centre Hospitalier Universitaire de Besancon; Centre Hospitalier Universitaire de Besancon; French Society for Intensive Care; SmithKline Beecham; GlaxoSmithKline
Completed - verified March 2012
Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma

Condition: Mantle Cell Lymphoma
Intervention: Other: R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline
Recruiting - verified March 2012
A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia

Conditions: Myelodysplastic Syndromes (MDS); Acute Myeloid Leukaemia (AML)
Intervention: Drug: Azacitidine and eltrombopag
Sponsors: Peter MacCallum Cancer Centre, Australia; Peter MacCallum Cancer Centre, Australia; GlaxoSmithKline; Celgene Corporation
Recruiting - verified December 2011
Physician Initiated Request for Migalastat in Individual Patients With Fabry Disease

Condition: Fabry
Intervention: Drug: migalastat HCl
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Amicus Therapeutics
Available - verified December 2011
A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)

Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo; Drug: Belimumab 200 mg SC
Sponsors: Human Genome Sciences; Human Genome Sciences; GlaxoSmithKline
Recruiting - verified January 2012
GSK2251052 Mass Balance in Healthy Adult Subjects

Condition: Community-acquired Infection
Intervention: Drug: 14C GSK2251052
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified December 2011
Provoked Craving Relief Study by NRT

Condition: Smoking Cessation
Intervention: Drug: nicotine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations

Condition: Healthy Volunteer
Interventions: Drug: Experimental paracetamol formulation; Drug: Marketed paracetamol; Drug: Higher dose marketed paracetamol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma

Condition: Carcinoma, Renal Cell
Intervention: Drug: Pazopanib followed by everolimus
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Pharmacokinetic (PK) Profiles of Tenofovir Disoproxil Fumarate (TDF) 300 mg in Healthy Chinese Subjects

Condition: Hepatitis B, Chronic
Intervention: Drug: TDF tablets
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012
Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Biological: albiglutide; Biological: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified January 2012
A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms

Condition: Overweight
Interventions: Drug: 120 mg orlistat; Drug: 60 mg orlistat; Drug: orlistat experimental dose
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs

Condition: Hepatitis B, Chronic
Intervention: Drug: GSK548470 300 mg tablet
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Airflow Limitation in Cardiac Diseases in Europe

Condition: Cardiovascular Disease
Intervention: Procedure: Spirometry
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
The Effects of Potassium Nitrate in Reducing Dentinal Hypersensitivity

Conditions: Dentinal Sensitivity; Dental Pain
Interventions: Drug: Potassium Nitrate; Drug: Potassium Nitrate; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects

Condition: Cough
Interventions: Drug: GSK2339345 (solution); Drug: GSK2339345 (nebulised); Drug: Placebo (0.9% sodium chloride solution); Drug: Lidocaine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
A Pharmacokinetic Study of an Experimental Paracetamol Formulation

Condition: Headache, Tension-Type
Interventions: Drug: Experimental paracetamol; Drug: Paracetamol marketed formulation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011
A Study to Compare Two Paracetamol Formulations.

Condition: Pain
Interventions: Drug: Marketed paracetamol; Drug: Experimental paracetamol formulation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

Condition: Asthma
Interventions: Drug: ADVAIR 100/50mcg; Drug: ADVAIR 250/50mcg; Drug: ADVAIR 500/50mcg; Drug: FLOVENT 100mcg; Drug: FLOVENT 250mcg; Drug: FLOVENT 500mcg
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Parexel
Recruiting - verified May 2012
Japanese Phase 1 Study of Mepolizumab

Condition: Asthma
Interventions: Biological: SB-240563; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified January 2012
Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer

Condition: Primary Invasive Breast Cancer
Intervention:
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012
Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)

Conditions: Myelodysplastic Syndrome; Thrombocytopenia
Intervention: Drug: Eltrombopag
Sponsors: Nordic MDS Group; Nordic MDS Group; GlaxoSmithKline
Recruiting - verified November 2011
Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features

Condition: Depressive Disorder, Major
Intervention: Drug: Bupropion extended release
Sponsors: The Catholic University of Korea; Chi-Un Pae; GlaxoSmithKline
Completed - verified November 2011
Long-term Effects of Dutasteride on Architectural and Nuclear Morphometric Features of Benign Prostate Tissue

Condition: Benign Prostate Tissue
Intervention:
Sponsors: University of Illinois; University of Illinois; GlaxoSmithKline
Active, not recruiting - verified November 2011
A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: GSK2376497; Drug: 0.9% sodium chloride
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.

Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012
Effects of a Common Cold Treatment on Cognitive Function

Condition: Common Cold
Interventions: Drug: Paracetamol and Caffeine; Drug: Paracetamol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011
A Pharmacokinetic Study Investigating the Rate and Extent of Paracetamol Absorption of Three Experimental Sustained Release Pediatric Suspensions

Condition: Healthy
Interventions: Drug: Paracetamol fast dissolution suspension; Drug: Paracetamol medium dissolution suspension; Drug: Paracetamol slow dissolution suspension; Drug: Paracetamol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
Evaluation of the Nicotine Lozenge in Relief of Provoked Acute Craving

Conditions: Smoking; Smoking Cessation
Interventions: Drug: Nicotine lower dose; Drug: Nicotine higher dose; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil® Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

Condition: Human Papillomavirus (HPV) Type 16/18 Infections
Interventions: Biological: Cervarix; Biological: Gardasil; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe COPD Patients.

Condition: Asthma
Interventions: Drug: SERETIDE Rotacaps; Drug: SERETIDE Diskus
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified December 2011
The Evaluation of Belimumab in Myasthenia Gravis (MG)

Condition: Myasthaenia Gravis
Interventions: Biological: Belimumab; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified February 2012
Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite

Condition: Epilepsy
Intervention: Drug: Retigabine / Ezogabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified January 2012
Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects

Condition: Epilepsy
Interventions: Drug: 50mg Ezogabine/retigabine; Drug: 100mg Ezogabine/retigabine; Drug: 200mg Ezogabine/retigabine; Drug: 400mg Ezogabine/retigabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of Ronacaleret in Healthy Human Volunteers

Condition: Bone Marrow Transplantation
Interventions: Drug: Ronacaleret (100mg tablet); Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified November 2011
6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old

Condition: Asthma
Interventions: Drug: ADVAIR 100/50mcg; Drug: ADVAIR 250/50mcg; Drug: FLOVENT 100mcg; Drug: FLOVENT 250mcg
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Parexel
Recruiting - verified May 2012
Vaccine Effectiveness of RV1 in a Naïve Population

Conditions: Rotavirus Infections; Gastroenteritis; Diarrhea
Intervention:
Sponsors: McGill University Health Center; McGill University Health Center; Centre hospitalier universitaire Sainte-Justine; Centre Hospitalier Universitaire de Sherbrooke; Centre Hospitalier régional de Rimouski; Institut National en Santé Publique du Québec; Ministère de la santé et des services sociaux; GlaxoSmithKline
Recruiting - verified April 2012
Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.

Condition: Infections, Human Immunodeficiency Virus and Hepatitis
Interventions: Drug: Dolutegravir; Drug: Methadone
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Completed - verified March 2012
Fondaparinux in Critically Ill Patients With Renal Failure

Condition: Venous Thromboembolism
Intervention: Drug: Fondaparinux
Sponsors: Wayne State University; Wayne State University; GlaxoSmithKline
Not yet recruiting - verified November 2011
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately

Conditions: Hepatitis B; Diphtheria; Haemophilus Influenzae Type b (Hib); Poliomyelitis; Pertussis; Tetanus
Interventions: Biological: DTPa-HBV-IPV/Hib (Infanrix hexa™); Biological: DTPa-HBV-IPV (Infanrix penta™); Biological: Hib (Hiberix™)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine

Conditions: Hepatitis B; Diphtheria; Haemophilus Influenzae Type b (Hib); Poliomyelitis; Pertussis; Tetanus
Interventions: Biological: DTPa-HBV-IPV/Hib (Infanrix hexa™); Biological: OPV
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011
Migalastat Food Effect Study

Condition: Fabry Disease
Interventions: Drug: A (migalastat); Drug: B (migalastat); Drug: C (migalastat); Drug: D (migalastat); Drug: E (migalastat)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Condition: Multiple Sclerosis
Interventions: Drug: Ofatumumab 3mg; Drug: Ofatumumab 30mg; Drug: Ofatumumab 60mg; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Open-Label Phase 3 Long-Term Safety Study of Migalastat

Condition: Fabry Disease
Intervention: Drug: migalastat HCl 150mg
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Amicus Therapeutics
Recruiting - verified February 2012
A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab

Condition: Osteoporosis, Postmenopausal
Interventions: Drug: denosumab; Drug: placebo; Drug: open-label denosumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified December 2011
Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304

Condition: Epilepsy, Partial
Intervention: Drug: retigabine/ezogabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified January 2012
Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma

Condition: Angiosarcoma
Intervention: Drug: Pazopanib
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified October 2011
Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: current marketed FLOLAN (epoprostenol sodium); Drug: new thermo stable formulation of epoprostenol sodium
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course

Conditions: Hepatitis B; Diphtheria; Haemophilus Influenzae Type b (Hib); Poliomyelitis; Pertussis; Tetanus
Interventions: Biological: DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA); Biological: DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

Conditions: Breast Cancer; Breast Neoplasm
Intervention: Drug: Pazopanib
Sponsors: University of California, San Francisco; Hope Rugo, MD; GlaxoSmithKline
Recruiting - verified April 2012
Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly

Conditions: Hepatitis B; Diphtheria; Haemophilus Influenzae Type b (Hib); Poliomyelitis; Pertussis; Tetanus
Interventions: Biological: DTPa-HBV-IPV/Hib (Infanrix-hexa™); Biological: DTPa-IPV/Hib (Infanrix-IPV/Hib™); Biological: HBV (Engerix™-B)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011
A Study to Investigate the Effect of SB-705498 on Chronic Cough

Condition: Chronic Cough
Interventions: Drug: Placebo; Drug: SB-705498
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012
A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency

Condition: Cancer
Intervention: Drug: GSK2636771
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

Condition: Cancer
Interventions: Drug: GSK1120212; Drug: GSK2110183
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified November 2011
An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: rosiglitazone/glimepiride fix dose combination; Drug: glimepiride
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Terminated - verified December 2011
Bioavailability of Two Combination Products of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) in Asian Males.

Condition: Prostatic Hyperplasia
Interventions: Drug: Dutasteride (0.5mg); Drug: FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg); Drug: Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified December 2011
Phase IV Observational Study in Chronic Lymphocytic Leukemia

Condition: Leukaemia, Lymphocytic, Chronic
Intervention: Drug: Arzerra
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified October 2011
A Study to Look at How GSK1325756 is Taken up by the Body When Given by Mouth When Stomach Acid is Reduced

Condition: Pulmonary Disease, Chronic Obstructive
Intervention: Drug: GSK1325756
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
GSK1349572 Exposure in Blood, Seminal Fluid, and Rectal Fluid and Tissue in Healthy Male Subjects

Condition: Healthy
Intervention: Drug: dolutegravir
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; GlaxoSmithKline
Recruiting - verified December 2011
Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine

Conditions: Poliomyelitis; Haemophilus Influenzae Type b Disease; Hepatitis B; Diphtheria; Pertussis; Tetanus
Interventions: Biological: Combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and Haemophilus influenzae type b vaccine (GSK217744) - Formulation A; Biological: Combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and Haemophilus influenzae type b vaccine (GSK217744) - Formulation B; Biological: Infanrix hexaTM; Biological: Pfizer's 13-valent pneumococcal polysaccharide conjugate vaccine (Prevenar 13®)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

Condition: Colitis, Ulcerative
Intervention: Drug: SRT2104
Sponsors: GlaxoSmithKline; Sirtris, a GSK Company; GlaxoSmithKline
Recruiting - verified March 2012
IPF Drug Deposition Study

Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: Salbutamol
Sponsors: Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton & Harefield NHS Foundation Trust; GlaxoSmithKline
Recruiting - verified April 2012
Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine

Conditions: Haemophilus Influenzae Type b Disease; Diphtheria; Poliomyelitis; Pertussis; Tetanus
Interventions: Biological: Infanrix+Hib™; Biological: Poliorix™
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL

Conditions: CLL; SLL
Interventions: Drug: Ofatumumab; Drug: High-Dose Methylprednisolone; Drug: Alemtuzumab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified December 2011
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Ofatumumab
Sponsors: Grupo Espanol de trasplantes hematopoyeticos y terapia celular; Grupo Espanol de trasplantes hematopoyeticos y terapia celular; GlaxoSmithKline
Recruiting - verified January 2012
Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

Condition: Asthma
Interventions: Drug: Fluticasone Furoate; Drug: Fluticasone Furoate/Vilanterol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified May 2012
Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557

Condition: Asthma
Interventions: Drug: GSK2269557; Drug: GSK2269557 matching placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified February 2012
Hepatic Monitoring for Pazopanib

Condition: Carcinoma, Renal Cell
Interventions: Drug: Pazopanib use; Drug: Use of sunitinib, bevacizumab, or sorafenib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified October 2011
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults

Condition: Hepatitis C, Chronic
Interventions: Drug: Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose); Drug: Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified December 2011
An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy Volunteers

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: GSK961081 800 microgramme dose; Drug: Fluticasone Propionate 500 microgramme dose; Drug: GSK961081 800 microgramme and Fluticasone Propionate 500 microgramme separately; Drug: GSK961081 800 microgramme Fluticasone Propionate 500 microgrammes in a blend
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified May 2012
Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

Condition: Smoking Cessation
Interventions: Drug: Placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer; GlaxoSmithKline
Recruiting - verified May 2012
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212

Condition: Breast Cancer
Intervention: Drug: GSK1120212
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; GlaxoSmithKline
Recruiting - verified February 2012
A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)

Condition: Muscular Dystrophies
Interventions: Drug: GSK2402968 3mg/kg/week; Drug: GSK2402968 6 mg/kg/week; Drug: Placebo to match GSK2402968 3 mg/kg/week; Drug: Placebo to match GSK2402968 6 mg/kg/week
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Cardiovascular and Torsades de Pointes Monitoring for Pazopanib

Condition: Carcinoma, Renal Cell
Interventions: Drug: Pazopanib; Drug: Other anti-VEGFs
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified September 2011
Gabapentin and Donepezil Combination on Experimental Human Pain Models

Condition: Pain, Neuropathic
Interventions: Drug: Gabapentin lower dose; Drug: Donepezil; Other: Placebo (Dop); Other: Placebo (Gaba); Drug: Gabapentin higher dose
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
Safety of Inhaled Zanamivir in Pregnancy

Condition: Influenza, Human
Intervention: Drug: Treatment with zanamivir
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified October 2011
To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects

Conditions: Nausea and Vomiting, Chemotherapy-Induced; Nausea and Vomiting, Postoperative
Interventions: Drug: ondansetron; Drug: moxifloxacin; Other: saline
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012
31P MRS Ischaemic Exercise Optimisation and COPD

Condition: Atrophy, Muscular
Intervention: Other: MRI scan
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011
Drug Use Investigation for XYZAL (Levocetirizine)

Condition: Rhinitis, Allergic, Perennial and Seasonal
Intervention: Drug: Levocetirizine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified September 2011
Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)

Condition: Chronic Hepatitis C Infection
Interventions: Drug: Valacyclovir; Drug: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; GlaxoSmithKline
Recruiting - verified March 2012
Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: dolutegravir 50 mg OAD; Drug: darunavir 800mg OAD; Drug: ritonavir 100mg OAD
Sponsors: ViiV Healthcare; ViiV Healthcare; GlaxoSmithKline
Recruiting - verified February 2012
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Conditions: Pancreatic Alpha Cell Carcinoma; Pancreatic Beta Islet Cell Carcinoma; Pancreatic Delta Cell Carcinoma; Pancreatic G-cell Carcinoma; Recurrent Islet Cell Carcinoma
Interventions: Drug: temozolomide; Drug: pazopanib hydrochloride
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center; National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified November 2011
An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

Condition: Healthy Volunteers - Influenza A and/or B (GSK Biologicals' Influenza Candidate Vaccine GSK2321138A)
Interventions: Biological: Influenza vaccine GSK2321138A; Biological: Havrix Junior; Biological: Wyeth Prevenar; Biological: Sanofi Pasteur Varivax/ProVarivax; Biological: Varilrix
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.

Condition: Purpura, Thrombocytopaenic, Idiopathic
Interventions: Drug: Belimumab; Drug: Normal saline placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified April 2012
Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim

Condition: Immune Thrombocytopenic Purpura
Interventions: Biological: Eltrombopag; Biological: Romiplostim
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified August 2011
ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)

Condition: Skin Infections, Bacterial
Intervention: Drug: ALTARGO(retapamulin)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012
Topiramate Bioequivalence Study Brazil - Fast

Condition: Epilepsy, Tonic-Clonic
Interventions: Drug: Topiramate coated tablet; Drug: Topamax® coated tablet
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified December 2011
Pilot Study of Patient's Adherence to TYKERB™/TYVERB™ + Capecitabine in Metastatic Breast Cancer

Condition: Neoplasms, Breast
Intervention: Other: non-drug intervention educational programme
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified November 2011
Phase II Study of Ofatumumab in Elderly Patients With Chronic Lymphocytic Leukemia (CLL)

Conditions: Advanced Cancers; Leukemia
Intervention: Drug: Ofatumumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified January 2012
A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

Condition: Recurrent Endometrial Cancer
Intervention: Drug: Lapatinib and ixempra
Sponsors: Chang Gung Memorial Hospital; Hung-Hsueh Chou; GlaxoSmithKline; Bristol-Myers Squibb
Enrolling by invitation - verified October 2011
Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy

Condition: Benign Prostatic Hyperplasia
Interventions: Drug: Early combination therapy; Drug: Delayed combination therapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified July 2011
Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-Cell Lymphomas

Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Bendamustine; Drug: Ofatumumab; Drug: Carboplatin; Drug: Etoposide; Procedure: CT Scan; Procedure: PET Scan; Genetic: Stem Cell Transplant (STC)
Sponsors: Thomas Jefferson University; Thomas Jefferson University; GlaxoSmithKline
Recruiting - verified January 2012
Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma

Condition: Asthma
Interventions: Drug: Fluticasone furoate 50mcg; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects

Condition: Acne Vulgaris
Interventions: Drug: GSK2585823(CLDM 1%-BPO 3% gel); Drug: CLDM 3% gel twice daily
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise

Condition: Activity/Exercise Induced Bronchospasm
Interventions: Drug: Fluticasone Furoate/Vilanterol Inhalation Powder; Drug: Fluticasone Propionate Inhalation Powder
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified October 2011
Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma

Condition: Asthma
Interventions: Drug: Fluticasone furoate 50mcg; Drug: Fluticasone propionate 100mcg; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Condition: Thrombocytopaenia
Interventions: Drug: eltrombopag; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine

Condition: Migraine Disorders
Interventions: Drug: Non-steroidal anti-inflammatory drug (NSAID); Drug: Triptan
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified September 2011
Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients

Condition: Asthma
Interventions: Drug: Higher-dose inhaled corticosteroids; Drug: Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified September 2011
Amoxicillin Bioequivalence Study Brazil - Fast

Condition: Infections, Bacterial
Interventions: Drug: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL; Drug: Amoxil® 500mg/5mL powder for oral suspension
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older

Condition: Influenza
Intervention: Biological: GSK Biologicals' quadrivalent split virion influenza FLU-Q-QIV vaccine GSK2833489A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011
Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC

Condition: Melanoma
Interventions: Drug: MAGE-A3 ASCI injections without Poly IC:LC; Drug: MAGE-A3 ASCI injections with Poly IC:LC
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; GlaxoSmithKline; Oncovir, Inc.
Recruiting - verified March 2012
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

Condition: Mantle Cell Lymphoma
Interventions: Biological: Ofatumumab; Other: Ofatumumab + Bendamustine
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline
Recruiting - verified January 2012
Observational Study on Rotavirus Gastroenteritis Epidemiology, Impact of Lyophilised vs. Liquid Formulation of Rotarix™

Condition: Rotavirus Gastroenteritis
Intervention: Other: Data collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified October 2011
Phase I Study of Colistin Methanesulfonate Sodium

Condition: Infections, Pseudomonas
Interventions: Drug: Colistimethate sodium; Drug: Saline
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011
Pazopanib in Von Hippel-Lindau (VHL) Syndrome

Condition: Von Hippel-Lindau Syndrome
Intervention: Drug: Pazopanib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified April 2012
Special Drug Use Investigation for Lamictal® (Lamotrigine) Bipolar

Condition: Bipolar Disorder
Intervention:
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified March 2012
Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment

Condition: Venous Thromboembolism
Intervention: Drug: Fondaparinux Sodium
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified January 2012
Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)

Condition: Venous Thromboembolism
Intervention: Drug: Fondaparinux sodium
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified January 2012
Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief From Dentinal Hypersensitivity

Conditions: Dentinal Sensitivity; Hypersensitivity
Interventions: Drug: Test Toothpaste; Drug: Negative Control Toothpaste
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012
Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects

Condition: Asthma
Interventions: Drug: GW642444; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011
Clinical Study of Lamotrigine to Treat Newly Diagnosed Typical Absence Seizure in Children and Adolescents

Condition: Epilepsy
Intervention: Drug: Lamictal
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy

Condition: Epilepsy
Intervention: Drug: Lamictal
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL)

Condition: Cancer
Intervention: Radiation: ML10
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Terminated - verified March 2012
A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: rilapladib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
[18F]PBR111 and Microglial Activation in Multiple Sclerosis

Condition: Multiple Sclerosis
Intervention: Radiation: [18F]PBR111
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012
Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects

Condition: Parkinson Disease
Intervention: Drug: Ropinirole
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified September 2011
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Conditions: Advanced Cancers; Solid Tumors
Interventions: Drug: Pazopanib; Drug: Everolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline; National Comprehensive Cancer Network
Recruiting - verified April 2012
Long-acting Beta Agonist Step Down Study

Condition: Asthma
Interventions: Drug: Fluticasone/Salmeterol Diskus; Drug: Fluticasone/Salmeterol Diskus; Drug: Fluticasone Diskus
Sponsors: Johns Hopkins University; Johns Hopkins University; American Lung Association; GlaxoSmithKline
Recruiting - verified May 2012
Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis

Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: GSK1223249; Other: Saline placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Terminated - verified May 2012
Intranasal SB-705498 in Non-allergic Rhinitis Patients

Conditions: Non-allergic Rhinitis; Rhinitis
Interventions: Drug: Placebo; Drug: SB-705498
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease

Condition: Tuberculosis
Interventions: Biological: GSK Biologicals' investigational TB vaccine GSK 692342; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified November 2011
Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805

Condition: Hepatitis B, Chronic
Interventions: Drug: GSK2336805 150mg; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011
PET Study to Study Tumour Apoptosis

Condition: Cancer
Intervention: Radiation: 18FML10
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Guys St Thomas Hospital; Imperial College London
Recruiting - verified August 2011
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

Condition: Cancer
Interventions: Drug: Part 1; Cohort 1; Drug: Part 1; Cohort 2; Drug: Part 2; Stage 1; Drug: Part 2, Stage 2
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Withdrawn - verified March 2012
Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine

Condition: Restless Legs Syndrome
Interventions: Drug: morphine Placebo; Drug: GEn 600 mg; Drug: Morphine; Drug: GEn Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011
Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents

Condition: Asthma
Interventions: Drug: GW685698; Drug: GW685698
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified May 2012
Migraine Treatment Satisfaction With Treximet Versus Concomitant 2 Aleve and Imitrex

Condition: Migraine
Interventions: Drug: Treximet; Drug: Imitrex and two Aleve
Sponsors: Wesley Headache Clinic; Stephen H. Landy, M.D.; GlaxoSmithKline
Completed - verified October 2011
Clinical Study to Evaluate the Safety and Efficacy of recMAGE-A3 + AS-15 in Patients From Which the Bladder is Removed Due to Muscle Invasive Bladder Cancer

Condition: Urinary Bladder Neoplasms
Interventions: Biological: recMAGE-A3 + AS15 ASCI; Biological: Placebo
Sponsors: European Association of Urology Research Foundation; European Association of Urology Research Foundation; GlaxoSmithKline
Recruiting - verified September 2011
Pulmonary Function, Chronic Obstructive Pulmonary Disease (COPD) Prevalence, and Systemic Inflammation in Chronic Heart Failure With or Without COPD

Conditions: Heart Failure; Pulmonary Disease, Chronic Obstructive; Inflammation
Interventions: Other: Pulmonary function tests; Other: Blood tests; Other: Questionnaires; Other: Chest radiograph
Sponsors: Rijnstate Hospital; Rijnstate Hospital; GlaxoSmithKline
Completed - verified September 2011
Eltrombopag for Management of Thrombocytopenia

Condition: Leukemia
Intervention: Drug: Eltrombopag
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified April 2012
Drug Exposure Registry for GSK2248761, an Investigational NNRTI

Conditions: Seizures; Infection, Human Immunodeficiency Virus
Intervention: Drug: GSK2248761
Sponsors: ViiV Healthcare; ViiV Healthcare; GlaxoSmithKline
Active, not recruiting - verified October 2011
A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

Condition: Meningococcal Meningitis
Interventions: Biological: placebo+ Combined Tetanus, Reduced Diphtheria Toxoid Acellular Pertussis Vaccine+Quadrivalent Human Papillomavirus Vaccine; Biological: MenACWY Conjugate Vaccine+Combined Tetanus, Reduced Diphtheria Toxoid,Acellular Pertussis Vaccine +Quadrivalent Human Papillomavirus Vaccine
Sponsors: Novartis; Novartis; Novartis Vaccines
Recruiting - verified April 2012
A PET Study in Healthy Volunteers

Condition: Depressive Disorder
Interventions: Radiation: [11C]PHNO; Drug: Aripiprazole
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified September 2011
Intranasal SB-705498 in Allergic Rhinitis (AR) Patients

Condition: Allergic Rhinitis
Interventions: Drug: SB-705498; Drug: FP; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
GSK2190915 Neutrophilic Asthma Study

Condition: Asthma
Interventions: Drug: GSK2190915 100mg; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified March 2012
SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhinitis

Conditions: Non-allergic Rhinitis; Rhinitis
Interventions: Drug: SB-705498; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

Condition: Influenza Infection
Intervention: Biological: GSK1557484A vaccine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified December 2011
Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study

Condition: Human Papillomavirus Infection
Intervention: Biological: CervarixTM (GSK580299)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified February 2012
Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer

Conditions: Solid Tumors; Advanced Thyroid Cancer
Intervention: Drug: Combination of pazopanib and GSK1120212
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified May 2012
A Systematic Review of Studies of Influenza Cross-protection After Natural Infection or Vaccination

Condition: Influenza
Intervention: Biological: Vaccines or Natural Infection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified September 2011
Absolute Bioavialability of GSK1120212

Condition: Cancer
Interventions: Drug: GSK1120212; Drug: GSK1120212B
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers

Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: GSK2018682; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012
Study to Compare the Bioavailability of Dutasteride Novel Formulation Form to the Soft Gel Capsule Form in Healthy Male Subjects

Condition: Prostatic Hyperplasia
Interventions: Drug: dutasteride; Drug: dutasteride
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: GSK2110183; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
H1N1 Vaccine Safety in Manitoba, Canada

Condition: H1N1 Influenza
Intervention:
Sponsors: International Centre for Infectious Diseases, Canada; International Centre for Infectious Diseases, Canada; GlaxoSmithKline
Active, not recruiting - verified August 2011
Drug Interaction Study Between Dolutegravir and Prednisone

Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Dolutegravir; Drug: Prednisone
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Completed - verified October 2011
Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer

Conditions: Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer
Interventions: Drug: Carboplatin; Drug: background treatment according to standards fpr triple negative and Her2pos breast cancer patients
Sponsors: German Breast Group; German Breast Group; Cephalon; Roche Pharma AG; GlaxoSmithKline
Recruiting - verified February 2012
Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient

Condition: Alzheimer's Disease
Interventions: Biological: GSK933776; Biological: GSK933776; Biological: GSK933776
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified November 2011
Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection

Condition: Thromboembolism
Intervention:
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified August 2011
Fondaparinux EU-RMP (Adherence)

Conditions: ST-elevation Myocardial Infarction; Unstable Angina; Non ST Segment Elevation Myocardial Infarction; Acute Coronary Syndrome
Intervention: Drug: fondaparinux
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified August 2011
Special Drug Use Investigation for CLAVAMOX® (Amoxicillin/Clavulanate) Pediatrics Dry Syrup (Every Indication Excluded Otitis Media)

Condition: Otitis Maedia
Intervention: Drug: Amoxicillin and clavulanate
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified July 2011
Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)

Condition: Hypertension, Pulmonary
Intervention: Drug: Ambrisentan
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified August 2011
Albiglutide Thorough ECG Study in Healthy Volunteers

Condition: Healthy Subjects
Interventions: Biological: Albiglutide; Drug: Moxifloxacin
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012
Study to Assess the Effect of Gabepentin Enacarbil on Simulated Driving in Healthy Subjects

Conditions: Restless Legs Syndrome; Restless Legs Syndrome (RLS)
Interventions: Drug: gabapentin enacarbill; Drug: diphenhydramine; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011
Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation

Condition: Sepsis
Interventions: Drug: SRT2379; Drug: Placebo
Sponsors: GlaxoSmithKline; Sirtris, a GSK Company; GlaxoSmithKline
Completed - verified February 2012
U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne

Condition: Acne Vulgaris
Intervention: Other: acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%
Sponsors: GlaxoSmithKline; Stiefel, a GSK Company; GlaxoSmithKline
Completed - verified April 2012
Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment

Condition: Anaemia
Intervention: Drug: 5 mg GSK1278863
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Suspended - verified November 2011
SAP Depleter Dose Assessment Study in Patients

Condition: Amyloidosis
Intervention: Drug: GSK2315698
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified November 2011
Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects

Condition: Acne Vulgaris
Interventions: Drug: GI148512; Drug: vehicle gel
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified February 2012
Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics.

Condition: Asthma
Interventions: Drug: 100 micrograms Fluticasone propionate; Drug: 500 micrograms Fluticasone propionate; Drug: lactose powder
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified January 2012
Risk of Urinary Retention With Retigabine

Conditions: Epilepsy; Urinary Retention
Interventions: Drug: Non-EZG containing AED polytherapy; Drug: EZG containing AED polytherapy; Drug: Non-EZG AED monotherapy; Drug: EZG AED monotherapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified October 2011
Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH

Condition: NASH (Non-alcoholic Steato-hepatitis)
Interventions: Drug: Rosiglitazone; Drug: alpha-lipoic acid; Drug: Rosiglitazone/alpha-lipoic acid
Sponsors: Seoul St. Mary's Hospital; Seoul St. Mary's Hospital; GlaxoSmithKline
Terminated - verified January 2004
Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma

Condition: Recurrent, Persistent or Metastasized Cervical Cancer
Interventions: Drug: Paclitaxel; Drug: Cisplatin/Paclitaxel
Sponsors: Institut fuer Frauengesundheit; Institut fuer Frauengesundheit; GlaxoSmithKline; Schantl Pharma Service, Germany
Active, not recruiting - verified September 2006
GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue in Healthy Female Subjects

Condition: Healthy Adult Females
Intervention: Drug: GSK1349572 (dolutegravir)
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; GlaxoSmithKline
Active, not recruiting - verified May 2012
A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI); Drug: Tiotropium
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone Propionate / Salmeterol Xinafoate Combination (FSC); Drug: Anticholinergics (AC)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified July 2011
Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Condition: Respiratory Disorders
Intervention: Drug: Salmeterol and Fluticasone
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Condition: Respiratory Disorders
Intervention: Drug: Salmeterol and Fluticasone
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified June 2011
Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors

Conditions: Unspecified Adult Solid Tumor - Protocol Specific; Breast Cancer - Female
Interventions: Drug: Pazopanib; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI); GlaxoSmithKline
Recruiting - verified September 2011
Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

Conditions: Recurrent Thyroid Cancer; Stage IVA Follicular Thyroid Cancer; Stage IVA Papillary Thyroid Cancer; Stage IVB Follicular Thyroid Cancer; Stage IVB Papillary Thyroid Cancer; Stage IVC Follicular Thyroid Cancer; Stage IVC Papillary Thyroid Cancer
Interventions: Drug: pazopanib hydrochloride; Radiation: iodine I 131
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI); National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified February 2012
Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database

Condition: Epilepsy
Intervention: Drug: Anti-epileptic drug (AED)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012
Study to Assess the Safety and Immunological Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI

Condition: Melanoma
Intervention: Other: recMAGE-A3 + AS15 ASCI
Sponsors: University of Virginia; Craig L Slingluff, Jr; GlaxoSmithKline
Recruiting - verified August 2011
Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children

Condition: Dengue Virus Infection
Interventions: Other: Data collection; Procedure: Blood sample collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified October 2011
Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage

Condition: Retinoblastoma
Intervention: Drug: Melphalan
Sponsors: Hospital Sant Joan de Deu; Hospital Sant Joan de Deu; Fundació Sant Joan de Déu; Hospital General de Catalunya; Ministry of Health, Spain
Recruiting - verified March 2012
Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)

Condition: Cardiovascular Disease
Intervention: Drug: Fondaparinux Sodium
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified July 2011
Observational Study in Endoscopic Ablation Using Light Energy (ENABLE) Clinical Trials

Conditions: Phlebitis; Hepatitis C; Unstable Angina; Deep Vein Thrombosis; Ischemic Stroke; Pulmonary Embolism; Ischaemic Attack, Transient; Thrombocytopenia; Thrombophlebitis; Myocardial Infarction; Portal Vein Thrombosis
Intervention: Drug: eltrombopag
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified October 2011
Special Drug Use Investigation for Botox® (Botulinum) Spasticity (BOTOX is a Registered Trademark of Allergan, Inc.)

Condition: Mumps
Intervention: Drug: Botulinum Toxin Type A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified August 2011
Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery

Condition: Cardiovascular Disease
Intervention: Drug: Fondaparinux Sodium
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified July 2011
Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2336805; Drug: Pegylated interferon alfa-2a; Drug: Ribavirin; Drug: GSK2336805 Matching Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Pharmaceutical Product Development Clinical Research Organization (CRO)
Recruiting - verified February 2012
Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)

Condition: Influenza, Human
Intervention: Drug: Zanamivir hydrate
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified July 2011
Korean Chronic Obstructive Pulmonary Disease(COPD) Assessment Test Validation Study

Condition: Pulmonary Disease, Chronic Obstructive
Intervention:
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011
Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)

Condition: Varicella
Intervention: Drug: Valaciclovir
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011
Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)

Condition: Genital Herpes
Intervention: Drug: Valaciclovir Hydrochloride.
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified July 2011
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+ NHL

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma
Interventions: Biological: ofatumumab; Drug: bortezomib; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Procedure: biopsy; Procedure: quality-of-life assessment; Genetic: polymorphism analysis; Other: flow cytometry
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.; GlaxoSmithKline
Recruiting - verified April 2012
Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults

Condition: Influenza
Interventions: Biological: Fluviral™; Biological: Fluzone®
Sponsors: GlaxoSmithKline; GlaxoSmithKline; ID BioMedical Corporation of Quebec
Completed - verified July 2011
Risk of Narcolepsy Associated With Administration of H1N1 Vaccine

Condition: Narcolepsy
Intervention: Other: No intervention
Sponsors: Hopital du Sacre-Coeur de Montreal; Hopital du Sacre-Coeur de Montreal; GlaxoSmithKline
Recruiting - verified July 2011
Drug Use Investigation for FLOLAN (Epoprostenol) Injection 0.5mg・1.5mg

Condition: Cardiovascular Disease
Intervention: Drug: Epoprostenol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: GSK573719; Drug: GSK573719; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

Condition: Gastrointestinal Stromal Tumor (GIST)
Intervention: Drug: Pazopanib
Sponsors: Stanford University; Kristen Ganjoo; GlaxoSmithKline
Recruiting - verified December 2011
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Condition: Kidney Cancer
Interventions: Drug: Pazopanib; Drug: Temsirolimus; Behavioral: Quality of Life Assessment; Drug: Benadryl
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Not yet recruiting - verified March 2012
A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data

Condition: Migraine Disorders
Interventions: Drug: Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap); Drug: Single-entity oral triptans
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified June 2011
Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy

Condition: Migraine Disorders
Interventions: Drug: Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap); Drug: Triptan monotherapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified June 2011
Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery

Condition: Thrombosis, Venous
Interventions: Drug: dalteparin; Drug: enoxaparin; Drug: fondaparinux; Drug: unfractionated heparin
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011
Evaluation of Long-term HPV Vaccine Efficacy

Condition: Uterine Cervical Cancer
Intervention: Procedure: Screening for cervical cancer
Sponsors: University of Tampere; University of Tampere; FinnMedi Oy; GlaxoSmithKline
Enrolling by invitation - verified April 2011
Trial of Low-Dose MTX and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma

Condition: Follicular Lymphoma
Intervention: Drug: Low dose methotrexate and Bexxar
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; GlaxoSmithKline
Recruiting - verified August 2011
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)

Condition: Carcinoma, Renal Cell
Intervention: Drug: Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified June 2011
Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Intervention: Drug: fluticasone propionate/salmeterol xinafoate combination
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012
At What Time Therapeutic Plasma Concentrations of Paracetamol Are Achieved in Two Marketed Formulations

Condition: Healthy Volunteer
Interventions: Drug: Paracetamol formulation 1; Drug: Paracetamol formulation 2
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
LRRK2 Mutation and Parkinson's Disease

Condition: Parkinson Disease
Interventions: Genetic: Healthy; Genetic: PKD Patients
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified February 2012
Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database

Condition: Prostatic Hyperplasia
Intervention: Drug: 5-alpha Reductase Inhibitor (5ARI)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified June 2011
Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese Males

Condition: Influenza, Human
Intervention: Drug: GR121167 Solution
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011
Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: FSC; Drug: ACs
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
BONVIVA(Ibandronate) PMS(Post-marketing Surveillance )

Condition: Osteoporosis
Intervention: Drug: Ibandronate
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012
Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: TIO; Drug: TIO+FSC
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
Outcomes Associated With Early or Delayed Maintenance Treatment Post-Chronic Obstructive Pulmonary Disease Exacerbation

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Early maintenance treatment; Drug: Delayed Maintenance treatment
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified September 2011
A Study to Compare Two Paracetamol Tablets

Condition: Healthy Volunteer
Interventions: Drug: Marketed paracetamol; Drug: Experimental paracetamol formulation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Withdrawn - verified March 2012
Special Drug Use Investigation for IMURAN (Azathioprine) Tablet (Pulmones Transplantation)

Condition: Antirejection
Intervention: Drug: Azathioprine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
A Single and Repeat Dose PK/PD Study to Characterise Biomarker Response in Healthy Subjects Treated With Azithromycin

Condition: Autoimmune Diseases
Interventions: Drug: Azithromycin - 250 mg; Drug: Azithromycin - 1000 mg; Drug: Azithromycin - 250 mg every other day for 3 weeks
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012
Drug Use Investigation for IMURAN (Azathioprine) Tablet (Hepatic Transplantation)

Condition: Antirejection
Intervention: Drug: Azathioprine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified July 2011
A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations

Condition: Analgesia
Interventions: Drug: Paracetamol; Drug: Paracetamol formulation 1; Drug: Paracetamol Formulation 2; Drug: Paracetamol formulation 3; Drug: Paracetamol formulation 4
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
Healthy Volunteer Study Using 3 Different Formulations of Firategrast

Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: A; Drug: B; Drug: C; Drug: D; Drug: E; Drug: F
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)

Condition: Carcinoma, Renal Cell
Intervention: Drug: Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified February 2012
HYPAZ: Hypertension Induced by Pazopanib

Conditions: Renal Cell Carcinoma; Soft Tissue Sarcoma; Glioblastoma; Ovarian Cancer; Cervical Cancer; Breast Cancer; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Pancreatic Cancer; Melanoma; Gastrointestinal Cancer
Intervention: Drug: Pazopanib
Sponsors: Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; University of Cambridge; GlaxoSmithKline; Cambridge Experimental Cancer Medicine Centre
Recruiting - verified June 2011
Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)

Conditions: Chronic Lymphocytic Leukemia; Thrombocytopenia
Interventions: Drug: Placebo; Drug: Eltrombopag
Sponsors: University of Ulm; University of Ulm; GlaxoSmithKline; German CLL Study Group; WiSP Wissenschaftlicher Service Pharma GmbH
Active, not recruiting - verified April 2012
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

Conditions: Cervical Cancer; HPV Type 16/18 Infections
Intervention: Biological: GSK Biologicals' HPV vaccine 580299
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified March 2012
Pazopanib Hydrochloride and Anastrozole Before Surgery in Treating Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer

Conditions: Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer
Interventions: Drug: anastrozole; Drug: pazopanib hydrochloride; Procedure: therapeutic conventional surgery
Sponsors: University of Arizona; University of Arizona; National Cancer Institute (NCI); GlaxoSmithKline
Terminated - verified May 2012
A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children

Condition: H5N1 Influenza
Interventions: Biological: GSK1562902A Formulation 1; Biological: GSK1562902A Formulation 2; Biological: HavrixTM; Biological: HavrixTM Junior
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified November 2011
Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg

Condition: Cancer
Intervention: Drug: Nelarabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified June 2011
European Cost of Asthma Treatment

Condition: Asthma
Intervention: Other: asthma control test
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance)

Condition: Osteoporosis
Intervention: Drug: Ibandronate
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database

Condition: Prostatic Hyperplasia
Intervention: Drug: 5ARI
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
A Study Assessing GW870086X's Potential to Cause Skin Thinning

Condition: Dermatitis, Atopic
Interventions: Drug: GW870086X 0.2%; Drug: GW870086X 2%; Drug: Clobetasol Propionate; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified July 2011
Drug Use Investigation for LAMICTAL (Lamotrigine)

Condition: Epilepsy
Intervention: Drug: Lamotrigine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified June 2011
First Time in Human Study Using GSK2330672

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: placebo; Drug: 0.1 mg GSK2330672; Drug: 0.3 mg GSK2330672; Drug: 1 mg GSK2330672; Drug: 3 mg GSK2330672; Drug: 10 mg GSK2330672; Drug: 30 mg GSK2330672; Drug: 60 mg GSK2330672
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011
A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin.

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: GSK256073 1mg; Drug: GSK256073 5mg; Drug: GSK256073 10mg; Drug: GSK256073 25mg; Drug: Placebo; Drug: Sitagliptin 100mg
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified June 2011
Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil)

Condition: Anaemia
Interventions: Drug: GSK1278863; Drug: GSK1278863 + food; Drug: Gemfibrozil
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Octagon Research Solutions, Incoporated
Completed - verified October 2011
Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: fluticasone propionate/salmeterol 250µg/50µg (FSC); Drug: tiotropium bromide (TIO)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011
Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse

Condition: Malaria, Vivax
Interventions: Drug: Chloroquine 600mg; Drug: Chloroquine 300mg; Drug: Tafenoquine 50mg; Drug: Tafenoquine 100mg; Drug: Tafenoquine 300mg; Drug: Tafenoquine 600mg; Drug: Primaquine 15mg
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Medicines for Malaria Venture
Not yet recruiting - verified July 2011
Japanese Phase 1 Study of GSK2585823

Condition: Acne Vulgaris
Interventions: Drug: GSK2585823; Drug: BPO 3%; Drug: BPO 5%; Other: Vehicle
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified August 2011
Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis)

Condition: Hepatitis B, Chronic
Intervention: Drug: Lamivudine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

Condition: Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions: Drug: Dolutegravir 50 mg tablet; Drug: Dolutegravir 50 mg oral granules
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Completed - verified September 2011
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Condition: Multiple Myeloma
Intervention: Biological: recMAGE-A3 Protein plus AS15 Adjuvant
Sponsors: Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; GlaxoSmithKline
Recruiting - verified May 2012
A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: fluticasone furoate/vilanterol; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012
Special Drug Use Investigation for PAXIL Tablet (Long-term)

Condition: Mental Disorders
Intervention: Drug: Paroxetine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real World

Condition: Heart Failure, Congestive
Intervention: Other: guideline adherence
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
NOGO-A in Multiple Sclerosis FTIH

Condition: Multiple Sclerosis
Interventions: Drug: Placebo; Drug: GSK1223249
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Terminated - verified September 2011
Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder)

Condition: Panic Disorder
Intervention: Drug: Paroxetine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
Drug Use Investigation for PAXIL Tablet

Condition: Mental Disorders
Intervention: Drug: Paroxetine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
GSK2251052 in Complicated Urinary Tract Infection

Conditions: Pyelonephritis; Infections, Urinary Tract
Interventions: Drug: GSK2251052; Drug: imipenem-cilastatin
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Suspended - verified March 2012
Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212

Conditions: Solid Tumours; Cancer
Intervention: Drug: GSK1120212
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progression)

Condition: Mental Disorders
Intervention: Drug: Paroxetine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
GSK2251052 in the Treatment of Complicated Intra-abdominal Infections

Condition: Infections, Intestinal
Interventions: Drug: Drug: GSK2251052; Drug: Meropenem
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Terminated - verified April 2012
Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)

Condition: Social Phobia
Intervention: Drug: Paroxetine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified June 2011
The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women

Condition: Osteoporosis, Postmenopausal
Intervention: Other: Fracture evaluation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
Drug Use Investigation for ALLERMIST

Condition: Rhinitis
Intervention: Drug: Fluticasone
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: GSK573719; Drug: GSK573719; Drug: GSK573719; Drug: GSK573719; Drug: GSK573719; Drug: GSK573719; Drug: Tiotropium; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011
Drug Use Investigation for AVOLVE (Dutasteride) (Benign Prostatic Hyperplasia)

Condition: Prostatic Hyperplasia
Intervention: Drug: Dutasteride
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified June 2011
GSK1120212 Food-effect Study

Condition: Cancer
Intervention: Drug: GSK1120212
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day)

Condition: Panic Disorder
Intervention: Drug: Paroxetine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
Long-term Safety Study for GSK573719/GW642444 in Japanese

Condition: Pulmonary Disease, Chronic Obstructive
Intervention: Drug: GSK573719/GW642444 Inhalation Powder
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified February 2012
Drug Use Investigation for REVOLADE (ITP)

Condition: Chronic Idiopathic Thrombocytopenic Purpura
Intervention: Drug: Eltrombopag
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified August 2011
First Time in Human Study (FTIH) With Positron Emission Tomography (PET)

Conditions: Schizophrenia; Healthy Volunteer
Interventions: Drug: GSK1144814; Drug: GSK1144814; Drug: GSK1144814
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet

Condition: Migraine Disorders
Intervention: Drug: Naratriptan
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified June 2011
"End of EXTEND: Observing for Cure in Patients With Chronic ITP"

Condition: Purpura, Thrombocytopenic, Idiopathic
Intervention: Other: Observational study
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; GlaxoSmithKline
Recruiting - verified June 2011
Pazopanib, Docetaxel, Prednisone Prostate

Condition: Prostate Cancer
Interventions: Drug: Pazopanib; Drug: Docetaxel; Drug: Pazopanib; Drug: Prednisone
Sponsors: Duke University; Duke University; GlaxoSmithKline
Recruiting - verified July 2011
Special Drug Use Investigation for ALLERMIST (Long Term)

Condition: Rhinitis
Intervention: Drug: Fluticasone
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified August 2011
Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults

Condition: Plasmodium Falciparum Malaria
Interventions: Biological: Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01); Biological: GSK Biologicals' malaria vaccine 257049
Sponsors: GlaxoSmithKline; GlaxoSmithKline; The PATH Malaria Vaccine Initiative (MVI); Crucell Holland BV
Suspended - verified March 2012
To Evaluate the Incidence of Acute Otitis Media in Children in Five East European Countries

Conditions: Otitis Media With Effusion; Acute Otitis Media
Interventions: Other: Data collection (Retrospective); Other: Data collection (Prospective)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012
CV Events in Emetogenic Chemotherapy

Conditions: Vomiting; Cardiovascular Event; Arterial Thromboembolic Event
Intervention: Drug: HEC or MEC
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
Pulmonary Hypertension, Quality of Life and Psychosocial Factors

Condition: Pulmonary Hypertension
Intervention: Behavioral: Evaluation of quality of life
Sponsors: University Hospital, Montpellier; University Hospital, Montpellier; GlaxoSmithKline
Recruiting - verified June 2011
Mepolizumab in Nasal Polyposis

Condition: Polyps, Nasal
Interventions: Drug: Mepolizumab; Drug: Placebo; Drug: Run In Medication
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Treatment Period 1 - IV dose of GSK573719; Drug: Treatment Period 2 - Oral dose of GSK573719
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified August 2011
Hyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL)

Condition: Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Mesna; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Ofatumumab; Drug: Methotrexate; Drug: Cytarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified May 2012
Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

Conditions: Healthy Subjects; Infection, Human Immunodeficiency Virus
Interventions: Drug: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg; Drug: Dolutegravir 50 mg; Drug: abacavir 600 mg/lamivudine 300 mg
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Completed - verified August 2011